Piper Sandler downgraded Ventyx Biosciences (VTYX) to Neutral from Overweight with a price target of $14, down from $21, after after Eli Lilly entered an agreement to acquire all outstanding shares of Ventyx for $14 in cash.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts
- Ventyx Biosciences downgraded to Perform from Outperform at Oppenheimer
- Hold Rating Maintained on Eli Lilly’s Acquisition of Ventyx Biosciences Amid Limited Upside and NLRP3 Uncertainty
- Ventyx Biosciences downgraded to Neutral from Buy at H.C. Wainwright
- Ventyx Biosciences downgraded to Neutral from Buy at UBS